Implementing a dengue vaccination programme—who, where and how? | Zendy

Hannah Clapham | Zendy; Bridget Wills | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Implementing a dengue vaccination programme—who, where and how?

Author(s) -

Hannah Clapham,

Bridget Wills

Publication year - 2018

Publication title -

transactions of the royal society of tropical medicine and hygiene

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.725

H-Index - 105

eISSN - 1878-3503

pISSN - 0035-9203

DOI - 10.1093/trstmh/try070

Subject(s) - dengue vaccine , dengue fever , vaccination , medicine , immune system , virology , immunology , dengue virus , environmental health

The complex interaction between dengue viruses and the human immune system means that development of a safe, effective dengue vaccine was never going to be simple. The only currently licenced dengue vaccine (Dengvaxia®) does, indeed, have a complex immune profile depending on recipients' immune status, meaning that use of this vaccine is not straightforward. This commentary reviews the recommendations for vaccine use to date, and discusses issues and opportunities related to the implementation of vaccination programmes in light of these recommendations. Future dengue vaccines may also have similar profiles, so it is vital that these issues are addressed now to ensure optimal use of vaccination in the fight against dengue globally.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research